JP5517613B2 - Composition for promoting blood equol production for non-equol producers - Google Patents

Description

  The present invention relates to a blood equol production promoting composition for non-equol producers.

Conventionally, isoflavones contained in soybean have been known to have beneficial effects such as prevention of osteoporosis, alleviation of climacteric symptoms, alleviation of PMS symptoms, prevention of breast cancer and prostate cancer.
In recent studies, it is known that equol, which is a metabolite of daidzein produced in the intestine, is produced by ingesting daidzein, which is a kind of isoflavone (Patent Document 1).

However, there are those who can produce equol in the body and those who cannot produce it due to individual differences, and the non-producer who does not have blood equol is unlikely to be expected to have a beneficial effect of isoflavone (Non-patent Document 1). Therefore, it is desired to provide a composition that can enjoy the physiological action of isoflavone even if it is a non-equol producer.
However, at present, there are few effective compositions that can increase the concentration of equol in the blood if ingested even by non-equol producers. Daisein and this are utilized to produce equol. It is known that there is a possibility that equol is increased (Non-patent Document 2) by a technique (Patent Document 2) in which a microorganism having an ability to do so is incorporated into a composition or a combination of soybean and green tea.

Among them, in Patent Document 2, it is an essential requirement of the invention to use a special equol-producing microorganism such as Bacteroides obatas in the composition in order to produce equol.
However, a technique that can easily increase the blood equol concentration without using such a special microorganism has not yet been provided.

(References)
JP 2005-232074 A International publication WO99 / 07392 Uesugi S, et al., Biofactors. 22 (1-4), 221-8, 2004. Miyanaga N, et al., Asian Pac J Cancer Prev., Aug-Dec, 4 (4), 297-301, 2003.

  An object of the present invention is to provide a composition and method effective for producing equol in blood, which is “for non-equol producers” who cannot metabolize daidzein in the body and cannot produce equol. There is.

      As a result of repeated researches to solve the above problems, the present inventors have to take in the starting material daidzein isoflavone in order to produce more stable equol in the body, In non-equol producers, it is not sufficient to ingest this alone, and it has been found that it is effective to ingest solid nonfat milk together with daidzein isoflavone, and the present invention has been completed. It was.

That is, the present invention for solving the above problems
1. A composition for promoting equol production in blood for non-equol producers, comprising daidzein-based isoflavones and non-fat milk solids;
2. A composition for promoting equol production in blood for non-equol producers, comprising daidzein-based isoflavones, wherein the usage is taken simultaneously with the non-fat milk solids,
3. A set of compositions for promoting equol production in blood for non-equol producers, comprising at least a composition comprising daidzein-based isoflavones and non-fat milk solids;
4). In order to promote the production of equol in the blood of non-equol producers, the use of daidzein isoflavones and milk, which is the simultaneous intake of daidzein isoflavones and non-fat milk solids.

  According to the present invention, it becomes possible to produce equol effectively in the body even if it is a non-equol producer who cannot normally produce equol in the body even if ingesting isoflavone, and the beneficial effect of isoflavone Can be enjoyed more efficiently.

  First, terms of the present invention will be described.

“Equol” is called 7-hydroxy-3 (4′-hydroxyphenyl) -chroman and has physiological effects such as prevention of osteoporosis and prevention of climacteric symptoms. It is a generally generated substance.
Human equol concentration can be measured using a high performance liquid chromatograph mass spectrometer (HPLC / MASS). For details, see Stephen Barnes etc. HPLC-Mass Spectometry Analysis of Isofavones, PSEBM, Vol 217: pp254- 262, 1998.

In the present invention, an equol non-producer refers to a person who does not have the ability to produce equol from isoflavone in the body when ingesting isoflavone.
Equol is produced by enterobacteria from daidzein-type isoflavones, and there are individual differences in production capacity. As described above, there are persons who have production ability and those who do not have production ability in each individual. Whether or not the subject who takes the composition of the present invention has equol production ability is determined as follows. And That is, when isoflavone 20mg was administered orally, blood was collected 3 hours later and analyzed using HPLC / MASS, if no equol was detected in the blood, it was detected even if it was a non-equol producer. It is determined that it is an equol producer.

    The “daidzein isoflavones” used in the composition for promoting equol production in blood for non-equol producers of the present invention are isoflavones having daidzein as an aglycon skeleton, and include daidzein and its glycosides and analogs. Specifically, it includes daidzein, malonyl daidzin, acetyl daidzin, succinyl daidzine and the like in addition to daidzein. In the composition of the present invention, daidzein-based isoflavones may be used alone, or materials containing these may be used. Examples of the material include extracts from plants containing isoflavones (legumes such as soybeans), soybeans, soybean hypocotyls, tofu, soy milk, fermented soy milk, natto and the like. In particular, it is preferable to use a soybean hypocotyl extract or a purified product thereof that has a high content of daidzein-based isoflavones and can be efficiently ingested.

  However, daidzein isoflavones are metabolized by intestinal bacteria in the body and converted into equol when ingested by equol producers. However, the ability to produce equol varies from person to person, and in the case of non-equol producers, simply taking daidzein isoflavone alone cannot increase the blood equol concentration stably, and the physiology of daidzein isoflavone It is difficult to make full use of functions.

The “non-fat milk solid” in the present invention refers to a component derived from milk excluding moisture and milk fat. Therefore, any non-fat milk solids can be used in the present invention without limitation. For example, milk may be used, and raw milk, cow milk, special milk, raw goat milk, pasteurized goat milk, raw noodle milk, ingredient-adjusted milk, low-fat milk, non-fat milk, processed milk, etc. may be used as milk. Can also be used as dairy products such as cream , cheese, ice cream, concentrated milk, defatted concentrated milk, sugar-free milk, sugar-free defatted milk, whole milk powder, skim milk powder, cream powder, whey powder, Protein concentrated whey powder, buttermilk powder, sweetened condensed milk, adjusted powdered milk, fermented milk, lactic acid bacteria beverage, milk beverage, and the like can be used.

  The intake of each raw material in the composition is appropriately set to 10 mg or more, preferably 20 mg or more of daidzein-based isoflavone per day, and the nonfat milk solid content is set to 5 g or more, preferably 8 g or more. It is appropriate to be done.

  The “composition” of the present invention is not limited as long as it is of a type that can be ingested by humans, and examples include those included in the category of pharmaceuticals, supplements, and foods.

  When the composition of the present invention is a medicine or supplement, it can be mixed with a carrier acceptable to the human body as necessary in addition to the essential raw material of the present invention, and can be formulated into various intake forms. Formulation can be performed according to a normal method. Examples of the carrier to be used include various types commonly used for ordinary drugs, such as diluents or excipients such as fillers, binders, disintegrants, surfactants and lubricants. The ingestion form is not particularly limited, and may be in the form of tablets, pills, powders, solutions, suspensions, emulsions, granules, hard capsules, soft capsules and the like.

  When the composition of the present invention is a food product, it can be mixed with a raw material that can be blended into a food if necessary in addition to the essential raw material of the present invention to prepare various foods. Types of foods include, for example, oil-in-water emulsified foods such as creams; water-in-oil emulsified foods such as margarine; beverages such as soft drinks, milk drinks, soups, miso soup; soy milk, fermented soy milk, soy protein drinks, tofu, Soy products such as natto, deep-fried oil, deep-fried chicken, ganmodoki; meat products such as hamburger, meatballs, fried chicken, nuggets; various prepared foods; baked goods such as cookies and biscuits; nutrition bars, chocolates, cakes, and frozen desserts And confectionery such as cereal, rice cake, soft candy, gum, and tablet; bread such as bread, confectionery bread, and donut; and cooked rice such as rice, sushi, and candy.

  Another functional component or a raw material containing the same may be used in combination with the composition of the present invention to impart an additive or synergistic effect. Other components are not particularly limited, for example, catechin, chlorogenic acid, tannin, hesperidin, proanthocyanidin, anthocyanin, glycyrrhizin, gallic acid, ellagic acid, cocoa polyphenol and other phenols, plant extracts containing these, mannose oligosaccharides, Functions such as oligosaccharides such as soybean oligosaccharide, dietary fiber such as chitin / chitosan, glucomannan, indigestible dextrin, amino sugar such as glucosamine, medium chain fatty acid, diacylglycerol, conjugated fatty acid fat, polyunsaturated fatty acid fat Oils and fats, lecithin, plant sterols, soy protein, soy β-conglycinin, soy peptides, peptides such as avian and seafood peptides, amino acids such as carnitine, valine, leucine, isoleucine, theanine, glucan, hydroxycitric acid, γ- A Commonly used in supplements and health foods such as minobutyric acid, phytic acid, capsaicin, gymnemic acid, lignin, coenzyme Q10, conduritol A, α-lipoic acid, β-glucan, soybean saponin can be used in combination. .

Next, specific embodiments of the present invention will be described.
The present invention as a whole has a common technical feature that equol production from daidzein isoflavones is promoted in the body by simultaneously ingesting non-fat milk solids together with the above-mentioned daidzein isoflavones for non-equol producers. It is what has.
In addition, the meaning of “take simultaneously” in the present invention is not limited to the case where the person to be ingested daidzein isoflavone and non-fat milk solids at the same time, and the timing of ingestion may be slightly shifted. included. It is also a concept that includes cases where the product is prescribed and recommended to take each separately at a certain frequency. In this case, it is important that the frequency of daidzein-based isoflavones and non-fat milk solids interact to substantially promote the production of blood equol. Although it cannot be generally said, it is appropriate that it is prescribed or recommended that daidzein-based isoflavones be taken at least once a week, preferably at least 3 times a week, more preferably at least 5 times a week. It is also appropriate that the non-fat milk solid content is prescribed or recommended to be taken at least 4 times a week, preferably at least 5 times a week. In particular, although the time for taking both components is not limited, it is more preferable that it is prescribed or recommended to take both at least once daily.
As long as it has the technical features as described above, the present invention can take various forms as follows.

(This first invention)
In the first invention, first, a composition containing both daidzein-based isoflavone and non-fat milk solids is used as a composition for promoting equol production in blood for non-equol producers. Non-equol producers can inevitably simultaneously take daidzein-based isoflavones and non-fat milk solids by taking this composition.

(This second invention)
Next, this 2nd invention is a composition containing daidzein-based isoflavones, and the usage of the composition is to be taken simultaneously with the non-fat milk solids. What is determined to be taken at the same time is a composition for promoting blood equol production for non-equol producers.
For example, as long as a composition containing only daidzein-based isoflavones is used for the same ingestion subjects and uses as in the present invention, and the usage is taken at the same time as the nonfat milk solids, the equol production promoting composition of the present invention It is contained in the aspect of.
Specifically, when a non-equol producer who is an ingestion person ingests a composition (A) containing daidzein-based isoflavones, the non-fat milk solid content (B) is used as a usage of the composition (A). When the subject prepares and is prescribed or recommended to be taken at the same time as the composition (A), the composition (A) corresponds to the blood equol production promoting composition of the present invention.

(The third invention)
Next, the third aspect of the present invention is a set of compositions for promoting equol production in blood for non-equol producers, comprising at least a composition containing daidzein-based isoflavones and non-fat milk solids.
That is, a product comprising a combination of a composition (A) containing daidzein-based isoflavone and a non-fat milk solid content (B) is exemplified, and is used for the same ingestion subject and application as in the present invention. As long as (A) and (B) are taken substantially simultaneously, they are included in the embodiments of the present invention.

(The fourth invention)
The fourth invention uses daidzein-based isoflavones and non-fat milk solids which are used by simultaneously ingesting daidzein-based isoflavones and non-fat milk solids in order to promote blood equol production by non-equol producers. Is the method. The specific mode of this method of use is not particularly limited as long as daidzein isoflavone and non-fat milk solids can be taken at the same time. For example, as disclosed in the first to third inventions described above, a method comprising preparing a composition containing both daidzein-based isoflavone and non-fat milk solids, and ingesting this composition, daidzein-based isoflavone A method comprising preparing a composition containing the composition and simultaneously ingesting the composition and a separately prepared nonfat milk solid, a composition comprising a daidzein-based isoflavone and a nonfat milk solid And a method of using the set at the same time is exemplified.

(The fifth invention)
The fifth aspect of the present invention is a method for promoting blood equol production, characterized in that non-equol producers are simultaneously ingested with daidzein isoflavones and non-fat milk solids. Any of these components may be used as described above with a non-equol producer as the subject of intake of these components, but by simultaneously ingesting these components, production of blood equol in the subject can be promoted.

Per tablet with 8 mg of soy hypocotyl extract “Soyaflavone HG” (Fuji Oil Co., Ltd.), isoflavone content 50% and Daidzein isoflavone ratio 50% in total isoflavones, plus lactose and sugar ester 0.3 g isoflavone tablets were prepared. When 10 tablets are taken, 80 mg is taken as the total amount of isoflavones and 20 mg is taken as daidzein-based isoflavones.
A total of 162 subjects were ingested, and 10 of the above isoflavone tablets were ingested. After about 3 hours, blood was collected and a blood test was performed by HPLC / MASS. As a result, 68 equol producers were found to have detected equol even slightly. There were 94 non-equol producers with no medium equol detected.
Of these, a total of 89 persons (including 31 equol producers and 58 non-equol producers) who were able to cooperate in the study were included in the study. Equol producers were grouped into E1 and E2 groups, non-equol producers were grouped into N1 to N3 groups, and in addition to the normal diet in each group, the test meals specified in Table 1 below were daily I took it once. The solid content of non-fat milk in milk is approximately 8.8% (17.6 g for 200 ml of milk) although it varies depending on the subject.
In the N1 group, it was only instructed to take each of the isoflavone tablets and milk once a day, and it was left up to the subject to decide at what timing each.

(Table 1)

  Blood was collected again 2 to 4 weeks after the start of ingestion of the test food, and it was examined how much of the non-equol producers changed to equol producers. As a result, the ratio of equol producers in each group was as shown in Table 2.

(Table 2)

  As a result, in the case of non-equol producers, only 20% of people were changed to equol producers by taking only isoflavone tablets (N2 group). However, when milk was taken simultaneously with isoflavone tablets, 29% after 2 weeks and 32% after 4 weeks changed to equol producers (Group N1). That is, by using the isoflavone tablet and milk in combination, daidzein-based isoflavone contained in the isoflavone tablet is converted to equol, and the production of equol in the blood of non-equol producers is promoted.

Claims (4)

It contains daidzein-based isoflavones selected from the group consisting of daidzein, daidzin, malonyl daidzin, acetyl daidzin and succinyl daidzin alone or as a soy hypocotyl extract or a purified product thereof, and contains non-fat milk solids equol non producers blood equol production accelerating composition, wherein (except the composition is a food, a composition containing a microorganism or formononetin has the ability to produce equol to assimilate daidzein. ). Containing daidzein isoflavone selected from the group consisting of daidzein, daidzin, malonyl daidzin, acetyl daidzin and succinyl daidzin alone or as a soy hypocotyl extract or a purified product thereof, which is used simultaneously with non-fat milk solids equol non producers blood equol production accelerating composition, characterized in that it (provided that the composition is a food composition containing a microorganism or formononetin has the ability to produce equol by utilizing daidzein And excluding.) It comprises at least a composition comprising a daidzein-based isoflavone selected from the group consisting of daidzein, daidzin, malonyl daidzin, acetyl daidzin and succinyl daidzin alone or as a soy hypocotyl extract or a purified product thereof and a non-fat milk solid wherein, equol set of non-producers of blood equol production accelerating composition (provided that the composition is a food, a composition containing a microorganism or formononetin has the ability to produce equol by utilizing daidzein except for.). The composition of Claim 1 set so that a daidzein type | system | group isoflavone might be ingested 10 mg or more and non-fat milk solid content 5g or more per day.